Cellectar Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Significant clinical progress was reported for targeted radiopharmaceuticals, including strong phase 2b results in Waldenstrom's macroglobulinemia and the launch of a triple-negative breast cancer study. Regulatory submissions are planned for 2026, with commercialization and partnership strategies underway.
-
Breakthrough and PRIME designations were secured for CLR 131 after strong phase II-B results in Waldenstrom's macroglobulinemia, with regulatory submissions planned in the U.S. and EU. The pipeline includes new studies in triple-negative breast and pancreatic cancers, leveraging a unique targeted radiotherapeutic platform.
Fiscal Year 2025
-
Significant regulatory and clinical progress was made in 2025, advancing iopofosine I 131 toward EU and US approvals, expanding the radiotherapeutic pipeline, and strengthening financials with reduced expenses and a $15.2 million capital raise. Robust 12-month clinical data and global partnerships position the company for key milestones in 2026.
-
Q3 2025 saw major regulatory progress for iopofosine I 131, including EMA eligibility for conditional approval and FDA Breakthrough Therapy Designation, while financial discipline extended cash runway into Q3 2026. Pipeline assets advanced, with CLR 125 phase 1b trial underway and CLR 225 phase I trial pending financing.
-
Strong progress in clinical and regulatory strategy, with iopofosine I-131 advancing toward accelerated approval in the U.S. and Europe. Cash runway extends into Q2 2026, and next-generation pipeline assets are moving toward clinical trials, pending funding.
-
Cash runway extends into Q4 2025 as R&D and G&A expenses decline sharply year-over-year. Regulatory progress continues for iopofosine I 131 in WM, with pivotal studies planned and EMA feedback expected in Q3 2025. Strategic alternatives are being explored.
-
The company is advancing its lead oncology asset, iopofosine I 131, for Waldenstrom's macroglobulinemia, with strong phase two results and a phase three trial planned following FDA guidance. Additional assets targeting pancreatic and triple-negative breast cancers are phase one ready for 2025, and non-dilutive licensing deals are being pursued to fund development.
-
A novel oncology platform targets lipid rafts in tumor cells, enabling delivery of diverse payloads. Lead asset iopofosine I-131 showed strong efficacy and safety in Waldenstrom's macroglobulinemia, with regulatory approval targeted in 12–18 months. Pipeline assets are advancing to phase I studies.
Fiscal Year 2024
-
Regulatory clarity was achieved for iopofosine in WM, with a Phase III study set to begin and strong clinical results supporting its potential. Cash runway extends into Q4 2025, with multiple financing events completed and non-dilutive funding options under evaluation.
-
CLOVER WaM study results support iopofosine I 131 as a potential first-in-class therapy for relapsed/refractory WM, with NDA submission delayed to Q1/Q2 2025 and commercial launch targeted for H2 2025. Cash runway extends into Q2 2025, with additional funding tied to regulatory milestones.
-
Pivotal trial data for iopofosine in WM showed an 80% overall response and 58.2% major response rate in a highly refractory population, supporting a Q4 2024 NDA submission. Cash and recent warrant proceeds fund operations into Q2 2025, with additional programs advancing.
-
The pivotal CLOVER-WaM study of iopofosine I-131 in heavily pretreated WM patients achieved a 56.4% major response rate and 80% overall response rate, with durable responses and a favorable safety profile. The therapy offers a fixed-duration, outpatient-administered option with broad applicability and significant market potential.